神経認知障害における重要な調節体としてのCCR5
Chew Tin Zar Aung1, Khawla Abuaqel1, Miou Zhou1
1College of Dental Medicine, Western University of Health Sciences, Pomona, CA, United States of America.
Experimental neurology
|August 30, 2025
まとめ
CCキモカイン受容体5型 (CCR5) は神経炎症と認知機能の重要な役割を果たします. CCR5を阻害することは神経認知障害の治療の可能性を示していますが,その複雑な役割には文脈特有の研究が必要です.
科学分野:
- 神経科学
- 免疫学
- 薬理学について
背景:
- CCキモカイン受容体5型 (CCR5) は,免疫反応とHIVの侵入における役割として認識されています.
- 新しい証拠は,神経炎症とシナプス可塑性を含む中枢神経系機能におけるCCR5の重要な関与を強調しています.
- CCR5は,認知機能に影響する幅広い神経疾患に関与しています.
研究 の 目的:
- 神経炎症,シナプス可塑性,および認知機能におけるCCR5の多面的な役割をレビューする.
- 様々な神経認知障害におけるCCR5の関与とその病理学的メカニズムを探求する.
- 神経認知障害に対する CCR5 標的の治療の可能性と複雑さについて議論する.
主な方法:
- 神経疾患におけるCCR5に関する既存の文献の統合的レビュー.
- 神経炎症カスケードおよび疾患特有の病理におけるCCR5の役割の分析.
- CCR5の遺伝的および薬学的抑制に関する研究の評価
主要な成果:
- CCR5は複数の神経疾患における神経細胞と膠質細胞で上位調節され,神経炎症と神経損傷を調節する.
- CCR5抑制は,神経炎症を軽減し,脳機能を維持し,認知を改善する可能性を臨床前モデルで示しています.
- 異なった発見は,CCR5の複雑で文脈に依存する役割を示唆し,いくつかの研究は保護効果を示唆している.
結論:
- CCR5は中枢神経系における神経炎症と認知機能の重要なレギュラーです.
- CCR5を標的とした治療は 神経認知障害の治療の可能性があるが,その複雑な役割は慎重に検討する必要がある.
- 将来の研究は,遺伝的背景,細胞特異的効果,効果的なCCR5標的介入のための文脈特異的なアプローチを考慮する必要があります.
関連する概念動画
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Role of Neurotransmitters in Memory
964
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
964
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K


